PortalPublikationenProstate cancer detection and dutasteride: utility and limit...

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

Standard

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. / Leeuwen, van; Kölble, Konrad; Huland, Hartwig; Huland, Hartwig; Hambrock, Thomas; Barentsz, Jelle; Schröder, Fritz H.

in: EUR UROL, Jahrgang 59, Nr. 2, 2, 2011, S. 183-190.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Leeuwen, V, Kölble, K, Huland, H, Huland, H, Hambrock, T, Barentsz, J & Schröder, FH 2011, 'Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.', EUR UROL, Jg. 59, Nr. 2, 2, S. 183-190. <http://www.ncbi.nlm.nih.gov/pubmed/21130560?dopt=Citation>

APA

Leeuwen, V., Kölble, K., Huland, H., Huland, H., Hambrock, T., Barentsz, J., & Schröder, F. H. (2011). Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. EUR UROL, 59(2), 183-190. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21130560?dopt=Citation

Vancouver

Leeuwen V, Kölble K, Huland H, Huland H, Hambrock T, Barentsz J et al. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies. EUR UROL. 2011;59(2):183-190. 2.

Bibtex

@article{4b33e9c6a3304b5ab2a8e15b07ad071a,
title = "Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.",
abstract = "We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5?-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa).",
keywords = "Biopsy, Humans, Male, Risk Factors, Prostate-Specific Antigen/*blood, 5-alpha Reductase Inhibitors/*therapeutic use, Azasteroids/*therapeutic use, *Prostatic Neoplasms/drug therapy/epidemiology/pathology, Biopsy, Humans, Male, Risk Factors, Prostate-Specific Antigen/*blood, 5-alpha Reductase Inhibitors/*therapeutic use, Azasteroids/*therapeutic use, *Prostatic Neoplasms/drug therapy/epidemiology/pathology",
author = "van Leeuwen and Konrad K{\"o}lble and Hartwig Huland and Hartwig Huland and Thomas Hambrock and Jelle Barentsz and Schr{\"o}der, {Fritz H}",
year = "2011",
language = "English",
volume = "59",
pages = "183--190",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

AU - Leeuwen, van

AU - Kölble, Konrad

AU - Huland, Hartwig

AU - Huland, Hartwig

AU - Hambrock, Thomas

AU - Barentsz, Jelle

AU - Schröder, Fritz H

PY - 2011

Y1 - 2011

N2 - We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5?-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa).

AB - We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5?-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa).

KW - Biopsy

KW - Humans

KW - Male

KW - Risk Factors

KW - Prostate-Specific Antigen/blood

KW - 5-alpha Reductase Inhibitors/therapeutic use

KW - Azasteroids/therapeutic use

KW - Prostatic Neoplasms/drug therapy/epidemiology/pathology

KW - Biopsy

KW - Humans

KW - Male

KW - Risk Factors

KW - Prostate-Specific Antigen/blood

KW - 5-alpha Reductase Inhibitors/therapeutic use

KW - Azasteroids/therapeutic use

KW - Prostatic Neoplasms/drug therapy/epidemiology/pathology

M3 - SCORING: Journal article

VL - 59

SP - 183

EP - 190

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 2

M1 - 2

ER -